MET and esophageal squamous cell carcinoma: Additionally, multitarget tyrosine kinase inhibitor (TKI) cabozantinib and AXL/c-MET selective inhibitor R428 both decreased AXL phosphorylation and TGFβ-induced E-cadherin expression (marker of EMT), cell viability, migration, and tumor growth in esophageal squamous cell carcinoma (ESCC) cells and xenograft models (78).